JAMA Psychiatry最新文献

{"title":"Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis.","authors":"Aureliane C S Pierret,Yuya Mizuno,Pippa Saunders,Eshaya Lim,Riccardo De Giorgi,Oliver D Howes,Robert A McCutcheon,Barbara McGowan,Piya Sen Gupta,Daniel Smith,Khalida Ismail,Toby Pillinger","doi":"10.1001/jamapsychiatry.2025.0679","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0679","url":null,"abstract":"ImportancePeople with obesity and diabetes have poorer psychiatric and cognitive outcomes and lower quality of life (QOL) compared with those without. Glucagon-like peptide 1 receptor agonists (GLP1-RAs) are treatments for diabetes and obesity that may also influence psychiatric outcomes.ObjectiveTo conduct a meta-analysis of randomized placebo-controlled trials to evaluate psychiatric, cognitive, and QOL outcomes with GLP1-RA treatment.Data SourcesMEDLINE, Embase, PsycINFO, and CENTRAL databases were searched from inception through June 24, 2024.Study SelectionDouble-blind placebo-controlled trials comparing GLP1-RA to placebo in adults with overweight/obesity and/or diabetes, reporting on psychiatric, cognition, or QOL outcomes, were included.Data Extraction and SynthesisData extraction was performed in parallel by 2 reviewers. Random-effects meta-analysis was performed. Effect size measures were log risk ratios (log[RR]) and standardized mean differences (Hedges g). The quality of studies was appraised using the Cochrane risk-of-bias tool (RoB2). Certainty of evidence was assessed via GRADEpro.Main Outcomes and MeasuresMain outcomes were risk of psychiatric adverse events (serious and nonserious) and change in mental health symptom severity, health-related quality of life, and cognition.ResultsEighty randomized clinical trials involving 107 860 patients were included in the meta-analysis. The mean (SD) age of participants across studies in the meta-analysis was 60.1 (7.1) years; 43 251 were female (40.1%) and 64 608 male (59.9%). GLP1-RA treatment was not associated with a significant difference in risk of serious psychiatric adverse events (log[RR] = -0.02; 95% CI, -0.20 to 0.17; P = .87) and nonserious psychiatric adverse events (log[RR] = -0.03; 95% CI, -0.21 to 0.16], P = .76), or depressive symptom change (g = 0.02; 95% CI, -0.51 to 0.55; P = .94), compared with placebo. GLP1-RA treatment was associated with improvements in restrained eating (g = 0.35; 95% CI, 0.13 to 0.57; P = .002) and emotional eating behavior (g = 0.32; 95% CI, 0.11 to 0.54; P = .003) and in mental health-related QOL (g = 0.15; 95% CI, 0.07 to 0.22; P < .001), physical health-related QOL (g = 0.20; 95% CI, 0.14 to 0.26; P < .001), diabetes-related QOL (g = 0.23; 95% CI, 0.15 to 0.32; P < .001), and weight-related QOL (g = 0.27; 95% CI, 0.18 to 0.35; P < .001) compared with placebo.Conclusions and RelevanceIn patients with overweight/obesity and/or diabetes , GLP1-RA treatment is not associated with increased risk of psychiatric adverse events or worsening depressive symptoms relative to placebo and is associated with improvements in QOL, restrained eating, and emotional eating behavior. These findings provide reassurance regarding the psychiatric safety profile of GLP1-RAs and suggest that GLP1-RA treatment contributes to both physical and emotional well-being.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"54 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Outcomes of Discontinuing Antipsychotics After Hospitalization in Older Adults.","authors":"Chun-Ting Yang,James M Wilkins,Elyse DiCesare,Kevin T Pritchard,Qiaoxi Chen,Yichi Zhang,Dae Hyun Kim,Kueiyu Joshua Lin","doi":"10.1001/jamapsychiatry.2025.0702","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0702","url":null,"abstract":"ImportanceAmong hospitalized older adults, prolonged use of antipsychotic medications (APMs) following hospital discharge may increase the risk of APM-associated adverse events. There are limited data on whether early discontinuation of APMs is associated with reduced adverse clinical outcomes compared with APM continuation after discharge.ObjectiveTo compare clinical outcomes between discontinuation vs continuation of APMs initiated to manage hospitalization-related delirium.Design, Setting, and ParticipantsThis population-based cohort study examining nationwide US Medicare claims data from July 1, 2013, through December 31, 2018, and data from a large deidentified US commercial health care database (Optum CDM) from July 1, 2004, through May 31, 2024, included adults aged 65 years and older without psychiatric disorders or previous use of APMs who filled an APM prescription within 30 days of hospital discharge. Using incidence density sampling, APM discontinuers (gap ≥45 days) were matched with continuers based on the type of APM prescribed, the time since their first APM prescription, and whether they had been admitted to intensive care units prior to the first APM prescription. Data analysis was performed from July 12, 2024, to December 25, 2024.ExposureDiscontinuation vs continuation of APMs.Main Outcomes and MeasuresPropensity score matching was applied to adjust for 162 covariates. Study outcomes included rehospitalization, specific rehospitalization reasons, and all-cause mortality. Hazard ratios (HRs) were estimated using the Cox proportional hazards model; estimates from the 2 databases were further pooled using the fixed-effects meta-analysis model.ResultsA total of 13 712 propensity score-matched pairs were included, for an overall sample of 27 424 adults (discontinuers: mean [SD] age, 81.86 [7.26] years; 7400 [54.0%] female; continuers: mean [SD] age, 81.86 [7.27] years; 7360 [53.7%] female). During the median (IQR) follow-up of 180 (87-180) days, APM discontinuation vs continuation was associated with significantly lower risks of rehospitalization (HR, 0.89 [95% CI, 0.85-0.94]), inpatient delirium (HR, 0.87 [95% CI, 0.79-0.96]), fall-related emergency department visits or hospitalizations (HR, 0.77 [95% CI, 0.67-0.90]), hospitalization with urinary tract infection (HR, 0.79 [95% CI, 0.66-0.94]), and all-cause mortality (HR, 0.77 [95% CI, 0.69-0.86]). There was no statistical difference in the risks of pneumonia (HR, 0.88 [95% CI, 0.73-1.06]) or stroke (HR, 1.22 [95% CI, 0.97-1.53]) between discontinuers and continuers. Subgroups by dementia status, type and dose of APM prescribed, and duration of APM exposure showed consistent results.Conclusions and RelevanceBased on 2 nationwide US cohorts including older adults without psychiatric disorders, APM discontinuation was associated with reduced risks of all-cause rehospitalization and mortality, suggesting the importance of minimizing the duration of APM use after acute hospitalization.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"38 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric Prognosis Following Index Suicide Attempts in Early Adolescents.","authors":"Tanner J Bommersbach,Grace Johnson,Vanessa K Pazdernik,J Michael Bostwick,Alastair J S McKean","doi":"10.1001/jamapsychiatry.2025.0673","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0673","url":null,"abstract":"ImportanceThe rates of suicide and suicide attempts are rising precipitously among early adolescents aged 10 to 14 years in the US. While suicide attempts in this age group are more common and associated with lower lethality than in older age groups, very little is known about these individuals' long-term social and psychiatric outcomes.ObjectivesTo examine the adult outcomes of individuals making index suicide attempts that came to medical attention between the ages of 10 and 14 years.Design, Setting, and ParticipantsThis population-based cohort constitutes a subsample (n = 164) of a previously reported retrospective-prospective study examining individuals who made index suicide attempts during a 22-year period (1986-2007) in Olmsted County, Minnesota.Main Outcomes and MeasuresTo collect outcome measures, the medical records of all individuals were queried until March 31, 2023, comprising up to 36 years of follow-up data after the index attempt. Measures included current social, psychiatric, and mortality outcomes as well as lifetime measures of psychiatric hospitalizations and repeat suicide attempts. K-means clustering generated adult groupings based on aggregates of psychiatric hospitalizations and repeat attempts. Multivariable logistic regression identified index attempt factors associated with poor adult outcomes.ResultsOf 164 individuals aged 10 to 14 years who made index attempts (128 [78.0%] female; mean [SD] age at index attempt, 13.7 [1.1] years), 3 (1.8%) died on the index attempt. In the follow-up period, no individuals died by suicide. K-means clustering generated a 2-group solution reflecting low (120 [80%]) and high (30 [20%]) rates of adult psychopathology. While a minority of the sample belonged to the high-rate group, characterized by multiple repeat attempts and hospitalizations, the majority had favorable social indicators and fewer reattempts and hospitalizations. Poor adult outcomes were associated with being male (odds ratio, 2.44; 95% CI, 1.00-5.80; P = .04) and having a psychiatric diagnosis prior to the index attempt (odds ratio, 3.27; 95% CI, 1.42-8.07; P = .007).Conclusions and RelevanceIn this sample of early adolescents with index suicide attempts followed into adulthood, all who died by suicide did so on the index attempt. While a small number of individuals went on to develop chronic severe psychopathology, the majority demonstrated little evidence of long-term impairment. Given this discrepancy, future studies should focus on using risk stratification after index attempts to direct postvention resources toward adolescents more susceptible to poor outcomes.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"35 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Architecture and Risk of Childhood Maltreatment Across 5 Psychiatric Diagnoses.","authors":"Trine Tollerup Nielsen,Paraskevi Bali,Jakob Grove,Christina Mohr-Jensen,Thomas Werge,Søren Dalsgaard,Anders D Børglum,Edmund Sonuga-Barke,Helen Minnis,Ditte Demontis,,Elizabeth C Corfield,Ludger Tbartz van Elst,Manuel Mattheisen,Melanie M de Wit,Mohammed Jashim Uddin,Richard J L Anney,Stephen W Scherer,Thomas Bourgeron,Tinca J C Polderman","doi":"10.1001/jamapsychiatry.2025.0828","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0828","url":null,"abstract":"ImportanceChildhood maltreatment (CM) is associated with psychiatric disorders. The underlying mechanisms are complex and involve genetics.ObjectiveTo investigate the polygenic architecture of CM-exposed individuals across psychiatric conditions and if genetics modulates absolute CM risk in the presence of high-impact risk factors such as parental psychiatric diagnoses.Design, Setting, and ParticipantsThe population-based case-cohort iPSYCH was used to analyze 13 polygenic scores (PGS) in CM-exposed individuals across 5 psychiatric International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnoses benchmarked against controls. Individuals were stratified into PGS quantiles, and absolute CM risk was calculated using Cox regression. Sex-specific analyses were also performed. Data were analyzed from June 2022 to December 2024.ExposuresPGS of phenotypes of psychiatric disorders, CM, educational attainment, and substance use.Main Outcomes and MeasuresPGSs were generated using summary statistics from genome-wide association studies of phenotypes representing psychiatric disorders, CM, educational attainment, and substance use and tested for their association with CM across psychiatric disorders.ResultsThis study included 102 856 individuals (mean [SD] age, 22.6 [7.1] years; 54 918 male [53.4%]) 8 to 35 years old. A total of 2179 CM-exposed individuals were analyzed across individuals with attention-deficit/hyperactivity disorder (ADHD; n = 22 674), autism (n = 18 941), schizophrenia (n = 6103), bipolar disorder (n = 3061), depression (n = 28 896), and controls (n = 34 689). PGSs for ADHD and educational attainment were associated with CM across all psychiatric diagnoses. The absolute CM risk was increased in the highest PGS groups, eg, for ADHD, the absolute CM risk was 5.6% in the highest ADHD-PGS quartile whereas it was only 3.3% in the lowest ADHD-PGS quartile (hazard rate ratio quantile 4 vs quantile 1 = 1.81; 95% CI, 1.47-2.22). CM risk was more than twice as high for children with parents with a psychiatric diagnosis (5.7%) than for children with parents without a psychiatric diagnosis (2.5%), but even in the presence of this risk factor, individuals could still be stratified into risk groups based on their genetics. No genetic differences between CM-exposed males and females were observed, but there were striking sex differences in absolute CM risk, which reached 5.6% for females in the highest ADHD-PGS quartile and 2.0% for males.Conclusions and RelevanceResults of this case-control study suggest that individuals with high ADHD-PRS and/or low educational attainment-PRS had an associated elevated risk of CM. Extra attention should be given to individuals at high risk for CM across all 5 psychiatric diagnoses, ie, females with a high ADHD-PGS and/or a parent diagnosed with a psychiatric disorder.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"1 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143926358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting and Representation of Race and Ethnicity in Clinical Trials of Pharmacotherapy for Mental Disorders: A Meta-Analysis.","authors":"Alessio Bellato,Joaquim Raduà,Antoine Stocker,Maude-Sophie Lockman,Anusha Lall,Vishnie Ravisankar,Sonia Obiokafor,Emma Machell,Sahar Haq,Dalia Albiaa,Anna Cabras,Douglas Teixeira Leffa,Catarina Manuel,Valeria Parlatini,Assia Riccioni,Christoph U Correll,Paolo Fusar-Poli,Marco Solmi,Samuele Cortese","doi":"10.1001/jamapsychiatry.2025.0666","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0666","url":null,"abstract":"ImportanceRepresentation of race and ethnicity in randomized clinical trials (RCTs) is critical for understanding treatment efficacy across populations with different racial and ethnic backgrounds.ObjectiveTo examine race and ethnicity representation and reporting across RCTs of pharmacotherapies for mental disorders.Data SourcesPubMed (Medline), Embase (Ovid), APA PsycInfo, and Web of Science were searched until March 1, 2024, to retrieve network meta-analyses including RCTs of pharmacotherapies for International Statistical Classification of Diseases and Related Health Problems, Tenth Revision mental disorders.Study SelectionRCTs that recruited people of any age with a diagnosis of a mental disorder and that tested the efficacy of any pharmacologic intervention vs any control arm.Data Extraction and SynthesisRandom-effects logit-transformed proportion meta-analyses were used to estimate prevalence rates of race and ethnicity groups and their temporal trends across RCTs and to compare US RCT prevalence rates with US Census data. The Preferred Reporting Items for Overviews of Reviews was used to report our review.Main Outcomes and MeasuresReporting of data and percentages of race and ethnicity. The year of publication, type of RCT, geographic location, age group, and sample size were also included. There were no deviations that occurred from the original protocol.ResultsData were obtained from 1683 RCTs (375 120 participants in total). Of these, 1363 (91.7% of participants) included participants aged 18 years or older; 680 RCTs (36.0% of participants) were from the US, 404 (17.1% of participants) were from Europe, and 293 (29.9% of participants) were from multiple geographic locations. Race and ethnicity were reported in 39.2% of RCTs; reporting was the highest in US-based RCTs (58.7%) and lowest in Central and South America (8.7%) and Asia and the Middle East (12.4%). Among participants, 2.7% (95% CI, 2.1%-3.5%) self-reported as Asian, 9.0% (95% CI, 8.1%-10.0%) as Black, 11.0% (95% CI, 9.1%-13.3%) as Hispanic among White, 80.2% (95% CI, 78.8%-81.5%) as White including Hispanic, and 5.8% (95% CI, 5.2%-6.4%) as other race or ethnicity, multiracial, or multiethnic. There was more frequent reporting of race and ethnicity in US RCTs (log odds increased by 0.066 each year) and less frequent reporting in non-US RCTs (log odds increased by 0.023 each year). Studies reporting race and ethnicity did not generally include larger sample sizes (mean sample size, 263.7 [95% CI, 15.0-860.3] participants) compared with those not reporting such data (mean sample size, 196.6 [95% CI, 12.0-601.3] participants), albeit not in all locations. In US RCTs, adults in the other or multiracial and multiethnic category were historically overrepresented, while adults in Asian, Black, Hispanic among White, and White including Hispanic categories were underrepresented; Asian, Black, and Hispanic among White children and adolescents are still currently underrepresented.Conclus","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"115 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating Treatment Effects From Observational Data-Calling It a Target Trial Does Not Make It One.","authors":"Krista F Huybrechts,Sonia Hernández-Díaz","doi":"10.1001/jamapsychiatry.2025.0663","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0663","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"101 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-Species Framework for Emotional Well-Being and Brain Aging: Lessons From Behavioral Neuroscience.","authors":"F Vankee Lin,Janine M Simmons,Adam Turnbull,Yi Zuo,Yeates Conwell,Kuan Hong Wang","doi":"10.1001/jamapsychiatry.2025.0581","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0581","url":null,"abstract":"ImportanceEmotional well-being (EWB) is an emerging therapeutic target for managing and preventing symptoms associated with Alzheimer disease and related dementias (ADRD). However, more research is needed to establish causal inferences between brain changes, EWB, and behavioral changes observed in typical aging and ADRD.ObservationsThis article presents a framework for using a cross-species behavioral neuroscience approach to study EWB and brain aging, adopting a well-established biobehavioral model that highlights the reciprocal roles of brain changes, EWB, and ADRD symptoms. First, the challenges and opportunities in this field are reviewed. Then, a practical solution to improve comparability between animal and human studies is proposed.Conclusions and RelevanceThe goal is to draw comprehensive parallels and distinctions that could enhance the understanding of the mechanisms linking brain aging, EWB, and ADRD symptomatic disturbances across different species.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"5 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment: An Individual Participant Data Meta-Analysis.","authors":"Lasse Brandt,Orestis Efthimiou,Spyridon Siafis,Johannes Schneider-Thoma,Heiner Stuke,Hakan Ayrilmaz,Alkomiet Hasan,Andreas Heinz,Stefan Gutwinski,John M Kane,Stefan Leucht","doi":"10.1001/jamapsychiatry.2025.0587","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0587","url":null,"abstract":"ImportanceIt has been hypothesized that the association between acute-phase treatment with antipsychotic (vs placebo) and outcomes might be larger in individuals who were not recently treated compared to recently treated individuals. However, evidence is still lacking.ObjectiveTo compare the association between antipsychotic (vs placebo) acute-phase treatment and outcomes in individuals who were not recently treated to recently treated individuals.Data SourcesThe Yale University Open Data Access Project's database was searched from inception to April 16, 2024 (PROSPERO CRD42021224350).Study SelectionWe included placebo-controlled antipsychotic acute-phase randomized clinical trials with participants with schizophrenia or schizoaffective disorder aged 18 years and older. Participants were divided into 2 groups: recently treated (treated with an antipsychotic before the start of randomized treatment) and not recently treated (not treated for ≥4 weeks before the start of randomized treatment).Data Extraction and SynthesisMultiple linear regression models were implemented to estimate difference in mean difference (DMD), defined as mean difference (antipsychotic vs placebo) in not recently treated minus mean difference in recently treated, and 95% confidence intervals in each study. DMD and 95% confidence intervals were synthesized across studies using a random effects meta-analysis model.Main Outcomes and MeasuresThe primary outcome was overall symptoms (Positive and Negative Syndrome Scale [PANSS] score after 6 weeks).ResultsA total of 470 trials were identified, of which 12 were eligible for the analysis. A total of 692 individuals were included in the not recently treated group and randomized to antipsychotic (n = 502) or placebo (n = 190), and 2089 individuals were included in the recently treated group and randomized to antipsychotic (n = 1513) or placebo (n = 576). Overall median (IQR) age of included individuals was 38 (30-48) years, and 998 individuals (35.9%) were female. No evidence of difference in the antipsychotic vs placebo outcomes was detected across the not recently treated and recently treated individuals (DMD, 0.8 PANSS points; 95% CI, -3.6 to 5.2). Not recently treated individuals had better outcomes with both the antipsychotic and placebo compared to recently treated individuals.Conclusions and RelevanceIn this individual participant data meta-analysis, the association between antipsychotic (vs placebo) acute-phase treatment and outcomes may be similar in individuals with and without recent treatment. Individuals who were not recently treated had better outcomes with both the antipsychotic and placebo compared with recently treated individuals.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"16 1","pages":""},"PeriodicalIF":25.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic Gaps and Digital Innovations in Therapy Trends-Reply.","authors":"Mark Olfson","doi":"10.1001/jamapsychiatry.2025.0108","DOIUrl":"10.1001/jamapsychiatry.2025.0108","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":" ","pages":"539-540"},"PeriodicalIF":22.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAMA Psychiatry Peer Reviewers in 2024.","authors":"","doi":"10.1001/jamapsychiatry.2025.0260","DOIUrl":"https://doi.org/10.1001/jamapsychiatry.2025.0260","url":null,"abstract":"","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"82 5","pages":"e250260"},"PeriodicalIF":22.5,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}